Werth VP, Hejazi E, Pena SM, et al. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis. ACR 2017, abstract 7L.
Patiënten met systemische JIA steeds vaker getroffen door fatale longziekte
dec 2019 | ILD, Juveniele idiopathische artritis